Fundraising FoxAmprion, Inc.
1 known investors
Find your way into Amprion, Inc.
Sign up to see every warm intro you have to Amprion, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Amprion, Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Amprion offers SAAmplify-αSYN, a clinically validated diagnostic test that detects misfolded (pathological) α-synuclein in cerebrospinal fluid to aid diagnosis of neurodegenerative disorders such as Parkinson's disease, Lewy body dementia, and Alzheimer's. The seed amplification assay is aimed at physicians and researchers, providing biology-based evidence to support diagnosis of mixed neurodegenerative pathologies.
Investors · 1
How we know: Decathlon Capital Partners's portfolio page · funding news · press coverage · Not right? Tell us
Non-dilutive funding · 10 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $685.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2019 | $1.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2018 | $217.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $2.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $2.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2016 | $1.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2015 | $223.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2013 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2012 | $165.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Amprion, Inc. do?
- Amprion offers SAAmplify-αSYN, a clinically validated diagnostic test that detects misfolded (pathological) α-synuclein in cerebrospinal fluid to aid diagnosis of neurodegenerative disorders such as Parkinson's disease, Lewy body dementia, and Alzheimer's. The seed amplification assay is aimed at physicians and researchers, providing biology-based evidence to support diagnosis of mixed neurodegenerative pathologies.
- Who are Amprion, Inc.'s investors?
- Amprion, Inc.'s investors include Decathlon Capital Partners.